Exhibit 10.19
CONVERTIBLE NOTE AND WARRANT
PURCHASE AGREEMENT
This Convertible Note and Warrant
Purchase Agreement (the “ Agreement ”) is made
as of ____________, by and between Helix BioMedix, Inc., a Delaware
corporation (the “ Company ”), and the
undersigned (the “ Investor ”).
1. Purchase and Sale; Closing
.
1.1 Purchase of Note .
Subject to the terms and conditions of this Agreement, the Company
agrees to sell to the Investor, and the Investor agrees to purchase
from the Company, a Convertible Promissory Note (the “
Note ”) in substantially the form attached hereto as
Exhibit A in the principal amount set forth on the
signature page hereto. The Note will be convertible into equity
securities of the Company upon the terms and conditions contained
in the form of Note attached hereto as Exhibit A .
Shares of equity securities of the Company issued upon conversion
of the Note are referred to herein as the “ Note
Shares .”
1.2 Purchase of Warrant .
Subject to the terms and conditions of this Agreement, the Company
agrees to sell to the Investor, and the Investor agrees to purchase
from the Company, a Warrant (the “ Warrant ”) in
substantially the form attached hereto as Exhibit B .
The Warrant will be exercisable for shares of the Company’s
Common Stock upon the terms and conditions contained in the form of
Warrant attached hereto as Exhibit B . Shares of the
Company’s Common Stock issued upon exercise of the Warrant
are referred to herein as the “ Warrant Shares
.” The Note, the Warrant, the Note Shares and the Warrant
Shares are sometimes collectively referred to herein as the “
Securities .”
1.3 Closing . The closing of
the sale and issuance of the Note and Warrant shall be held at such
time and place upon which the Company and the Investor shall agree
(hereinafter referred to as the “ Closing ”).
The date of the Closing is referred to herein as the “
Closing Date .”
2. Representations of the
Company .
The Company represents and warrants
to the Investor as follows:
2.1 Organization and Standing
. The Company is a corporation duly organized and existing under,
and by virtue of, the laws of the State of Delaware and is in good
standing under such laws.
2.2 Corporate Power . The
Company will have at the Closing all requisite legal and corporate
power and authority to execute and deliver this Agreement, to sell
and issue the Securities and to carry out and perform its
obligations under the terms of this Agreement.
2.3 Authorization . All
corporate action on the part of the Company necessary for the
authorization, execution, delivery and performance of this
Agreement by the Company, the authorization, sale, issuance and
delivery of the Note and the Warrant and the performance of all of
the Company’s obligations hereunder and thereunder has been
taken or will be taken prior to the Closing. This Agreement, the
Note and Warrant, when executed and delivered by the Company, shall
constitute valid and binding obligations of the Company,
enforceable in accordance with their respective terms, subject to
laws of general application relating to bankruptcy, insolvency and
the relief of debtors and rules of law governing specific
performance, injunctive relief or other equitable remedies. The
Note Shares, when issued in compliance with the provisions of the
Note, will be validly issued, fully paid and nonassessable, and
will be free of any liens or encumbrances, assuming that the
Investor takes the Note Shares with no notice thereof, other than
any liens or encumbrances created by or imposed upon the Investor;
provided, however, that the Note Shares will be
subject to restrictions on transfer
under state and/or federal securities laws. The Warrant Shares,
when issued in compliance with the provisions of the Warrant, will
be validly issued, fully paid and nonassessable, and will be free
of any liens or encumbrances, assuming that the Investor takes the
Warrant Shares with no notice thereof, other than any liens or
encumbrances created by or imposed upon the Investor; provided,
however, that the Warrant Shares will be subject to restrictions on
transfer under state and/or federal securities laws.
2.4 No Finder’s Fees .
No person is entitled, directly or indirectly, to compensation from
the Company by reason of any contract or understanding or contact
with the Company as a finder or broker in connection with this sale
and purchase of the Note and Warrant contemplated by this
Agreement. The Company agrees to indemnify and hold the Investor
harmless against and respect of any claim of brokerage or other
commissions or similar fees relative to this Agreement or the
transactions contemplated hereby which arises as a result of a
contract or understanding made by the Company with any such broker
or finder in connection with this sale and purchase of the Note and
Warrant contemplated by this Agreement.
3. Representations of
Investors . The Investor hereby represents and warrants to the
Company with respect to its purchase of the Note and Warrant as
follows:
3.1 Investment . The Investor
understands that the investment in the Securities is a speculative
investment and represents that it is aware of the business affairs
and financial condition of the Company and has acquired sufficient
information about the Company to reach an informed and
knowledgeable decision to acquire the Note and Warrant, and that it
is purchasing the Note and Warrant for investment for its own
account only and not with a view to, or for resale in connection
with, any “distribution” within the meaning of the
Securities Act of 1933, as amended (the “
Securities Act ”) or applicable state securities
laws. The Investor further represents that it understands that the
Securities have not been registered under the Securities Act or
applicable state securities laws by reason of specific exemptions
therefrom, which exemptions depend upon, among other things, the
bona fide nature of the Investor’s investment intent as
expressed herein. The Investor acknowledges and understands that
the Securities must be held indefinitely unless subsequently
registered under the Securities Act and qualified under applicable
state securities laws or unless exemptions from such registration
and qualification requirements are available and that the Company
is under no obligation to register or qualify the
Securities.
3.2 Accredited Investor . The
Investor is an accredited investor as defined in Rule 501(a) of
Regulation D promulgated under the Securities Act.
3.3 Access to Data . The
Investor acknowledges that it has received and reviewed this
Agreement and exhibits hereto. The Investor has had an opportunity
to discuss the Company’s business, management and financial
affairs with its officers and directors. The Investor understands
that such discussions as well as any written information issued by
the Company were intended to describe the aspects of the
Company’s business and prospects which it believes to be
material but were not necessarily a thorough or exhaustive
description.
3.4 No Finder’s Fees .
No person is entitled, directly or indirectly, to compensation from
the Investor by reason of any contract or understanding or contact
with the Investor as a finder or broker in connection with the sale
and purchase of the Note and Warrant contemplated by this
Agreement. Investor agrees to indemnify and hold the Company
harmless against and in respect of any claim for brokerage or other
commissions or similar fees relative to this Agreement or the
transactions contemplated hereby which arises as a result of a
contract or understanding made by the Investor with any such broker
or finder in connection with the sale and purchase of the Note and
Warrant contemplated by this Agreement.
-2-
3.5 Legends . The Investor
understands that the Securities, and any securities issued in
respect thereof or exchange therefor, may bear one or all of the
following legends:
(a) “THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AND HAVE BEEN ACQUIRED FOR INVESTMENT AND
NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION
THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF
COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF
1933.”
(b) Any legend required by the blue
sky laws of any state to the extent such laws are applicable to the
Securities represented by the certificate so legended.
4. Condition to Investor’s
Obligations at Closing . The Investor’s obligation to
purchase the Note and Warrant at the Closing is subject to the
fulfillment on or prior to the Closing Date of the following
condition:
4.1 Representations and
Warranties Correct . The representations and warranties made by
the Company in Section 2 hereof shall be true and correct when
made and shall be true and correct on the Closing Date.
5. Conditions to the
Company’s Obligations at Closing . The Company’s
obligation to sell and issue the Note and Warrant at the Closing is
subject to the fulfillment of the following conditions:
5.1 Representations and
Warranties Correct . The representations and warranties made by
the Investor in Section 3 hereof shall be true and correct
when made and shall be true and correct on the Closing
Date.
5.2 Qualifications . All
authorizations, approvals or permits, if any, of any governmental
authority or regulatory body of the United States or of any state
that are required in connection with the lawful issuance and sale
of the Securities pursuant to this Agreement shall be obtained and
effective as of the Closing.
5.3 Board Approval . The
Company’s Board of Directors shall have authorized the sale
and issuance of the Securities.
6. Miscellaneous .
6.1 Governing Law; Venue .
This Agreement, the Note and the Warrant shall in all respects be
governed by and construed and enforced in accordance with the laws
of the State of Washington, as such laws apply to contracts entered
into and wholly to be performed within such state. The parties
expressly stipulate that any litigation under this Agreement shall
be brought in the state courts of King County, Washington or in the
United States District Court for the Western District of
Washington. The parties agree to submit to the exclusive
jurisdiction and venue of those courts.
6.2 Successors and Assigns .
Except as otherwise provided herein, the provisions hereof shall
inure to the benefit of, and be binding upon, the successors,
assigns, heirs, executors and administrators of the parties hereto,
provided, however, that the rights of the Investor to purchase the
Note and Warrant shall not be assignable without the consent of the
Company and provided further that the Company may not assign its
rights hereunder.
-3-
6.3 Entire Agreement;
Amendment . This Agreement, the Note, the Warrant and the other
documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the
subject matter hereof and thereof, and no party shall be liable or
bound to any other party in any manner by any warranties,
representations or covenants except as specifically set forth
herein or therein. Except as expressly provided herein, neither
this Agreement nor any term hereof may be amended, waived,
discharged or terminated other than by a written instrument signed
by the party against whom enforcement of any such amendment,
waiver, discharge or termination is sought.
6.4 Notices, etc . All
notices and other communications under this Agreement shall be in
writing and shall be delivered in person, via facsimile machine,
sent by documented overnight delivery service, or mailed by
registered or certified mail, return receipt requested, postage
prepaid, addressed (a) if to the Investor, at the address of
the Investor set forth on the signature page of this Agreement, or
(b) if to the Company, to the attention of its President at
its principal offices at 22118 20th Avenue SE, Suite 204, Bothell,
WA 98021. Unless otherwise specified in this Agreement, all such
notices and other written communications shall be effective (and
considered delivered and received for the purposes of this
Agreement) (i) if delivered, upon delivery, (ii) if by
facsimile machine during normal business hours upon transmission
with confirmation of receipt by the receiving party’s
facsimile terminal and if not sent during normal business hours,
then on the next day, (iii) if sent by documented overnight
delivery service, on the date following the date on which such
notice is delivered to such overnight delivery service for mailing,
or (iv) if mailed via first-class regular mail, three
(3) day after depositing in the U.S. Mail.
6.5 Expenses; Attorneys Fees
. Each of the Company and the Investor shall each bear its own
expenses incurred on its behalf with respect to this Agreement and
the transactions contemplated hereby. Notwithstanding the
foregoing, if any action at law or in equity (including
arbitration) is necessary to enforce or interpret the terms of this
Agreement, the Note or the Warrant, the prevailing party shall be
entitled to reasonable attorney’s fees, costs and necessary
disbursements in addition to any other relief to which such party
may be entitled.
6.6 Counterparts . This
Agreement may be executed in any number of counterparts, each of
which shall be enforceable against the party or parties actually
executing such counterparts, and all of which together shall
constitute one instrument.
6.7 Titles and Subtitles .
The titles and subtitles used in this Agreement are used for
convenience only and are not considered in construing or
interpreting this Agreement.
[Remainder of Page Intentionally
Left Blank]
-4-
The foregoing Agreement is hereby
executed as of the date first above written.
|
|
|
|
COMPANY:
|
|
|
HELIX
BIOMEDIX, INC.
|
|
|
|
By:
|
|
|
|
|
R. Stephen
Beatty, President and
|
|
|
Chief Executive
Officer
|
|
|
INVESTOR:
|
|
|
|
|
Print name
|
|
|
Investment
Amount: $ _______________________
|
|
|
|
By:
|
|
|
|
|
Signature
|
|
|
|
Its:
|
|
|
|
|
Title
|
|
|
|
|
|
Soc. Sec. No. or Tax ID:
_____________________
|
[Signature Page to Convertible Note
and Warrant Purchase Agreement]
-5-
EXHIBIT A
THIS NOTE AND THE SECURITIES
ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY
STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A
REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES
UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR UNLESS (i)
SOLD PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND
APPLICABLE STATE SECURITIES LAWS AND (ii) AT THE OPTION OF THE
COMPANY, AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED HAS BEEN DELIVERED
TO THE COMPANY.
HELIX BIOMEDIX,
INC.
CONVERTIBLE PROMISSORY
NOTE
, 2008
FOR VALUE RECEIVED
, Helix BioMedix, Inc., a Delaware
corporation (“ Company ”), promises to pay to
(“ Holder ”), or his registered assigns, the
principal sum of
Dollars ($
), or such lesser amount as shall then equal the outstanding
principal amount hereof, together with interest from the date of
this Note on the unpaid principal balance at a rate equal to eight
percent (8%) per annum, computed on the basis of the actual number
of days elapsed. All unpaid principal, together with any then
unpaid and accrued interest and other amounts payable hereunder,
shall be due and payable on the earlier of (i) July 1, 2011 (the
“ Maturity Date ”) or (ii) when such amounts are
declared due and payable by the Holder or made automatically due
and payable, in each case upon or after the occurrence of an Event
of Default (as defined below). This Note is issued pursuant to the
Convertible Note Purchase Agreement of even date herewith (as
amended, modified or supplemented, the “ Purchase
Agreement ”) between Company and the Investor (as defined
in the Purchase Agreement) and is one of several convertible
promissory notes issued on or about the date hereof (the “
Notes ”).
The following is a statement of the
rights of Holder and the conditions to which this Note is subject,
and to which the Holder hereof, by the acceptance of this Note,
agrees:
1. Definitions
. As used in this Note,
the following capitalized terms have the following
meanings:
(a) “ Company ”
includes the corporation initially executing this Note and any
Person which shall succeed to or assume the obligations of Company
under this Note.
(b) “ Holder ”
shall mean the Person specified in the introductory paragraph of
this Note or any Person who shall at the time be the registered
holder of this Note.
(c) “ Person ”
shall mean and include an individual, a partnership, a corporation
(including a business trust), a joint stock company, a limited
liability company, an unincorporated association, a joint venture
or other entity or a governmental authority.
2. Interest
. Accrued interest on this Note
shall be payable at such time as the outstanding principal amount
hereof shall be paid in full.
3. Events of
Default . The
occurrence of any of the following shall constitute an “
Event of Default ” under this Note:
(a) Failure to Pay . Company
shall fail in any material respect to pay any principal payment,
any interest or other payment required under the terms of this Note
on the date due and such payment shall not have been made within
fifteen (15) days of Company’s receipt of Holder’s
written notice to Company of such failure to pay; or
(b) Breaches of Covenants .
Company shall fail in any material respect to observe or perform
any covenant, obligation, condition or agreement contained in this
Note (other than those covenants specified in Section 3(a) hereof)
and such failure shall continue for thirty (30) days after
Company’s receipt of Holder’s written notice to Company
thereof; or
(c) Representations and
Warranties . Any representation or warranty made by Company to
Holder in this Note shall be untrue in any material respect when
made; or
(d) Voluntary Bankruptcy or
Insolvency Proceedings . Company shall (i) apply for or consent
to the appointment of a receiver, trustee, liquidator or custodian
of itself or of all or a substantial part of its property, (ii)
admit in writing its inability to pay its debts generally as they
mature, (iii) make a general assignment for the benefit of its or
any of its creditors, (iv) be dissolved or liquidated in full or in
part, (v) commence a voluntary case or other proceeding seeking
liquidation, reorganization or other relief with respect to itself
or its debts under any bankruptcy, insolvency or other similar law
now or hereafter in effect or consent to any such relief or to the
appointment of or taking possession of its property by any official
in an involuntary case or other proceeding commenced against it, or
(vi) take any action for the purpose of effecting any of the
foregoing; or
(e) Involuntary Bankruptcy or
Insolvency Proceedings . Proceedings for the appointment of a
receiver, trustee, liquidator or custodian of Company or of all or
a substantial part of the property thereof, or an involuntary case
or other proceedings seeking liquidation, reorganization or other
relief with respect to Company or the debts thereof under any
bankruptcy, insolvency or other similar law now or hereafter in
effect shall be commenced and an order for relief entered or such
proceeding shall not be dismissed or discharged within sixty (60)
days of commencement.
4. Rights of Holder upon
Default . Upon the
occurrence or existence of any Event of Default (other than an
Event of Default referred to in Sections 3(d) and 3(e) hereof) and
at any time thereafter during the continuance of such Event of
Default, Holder may, by written notice to Company, declare all
outstanding obligations payable by Company hereunder to be
immediately due and payable without presentment, demand, protest or
any other notice of any kind, all of which are hereby expressly
waived, anything contained herein to the contrary notwithstanding.
Upon the occurrence or existence of any Event of Default described
in Sections 3(d) and 3(e) hereof, immediately and without notice,
all outstanding obligations payable by Company hereunder shall
automatically become immediately due and payable, without
presentment, demand, protest or any other notice of any kind, all
of which are hereby expressly waived, anything contained herein to
the contrary notwithstanding. In addition to the foregoing
remedies, upon the occurrence or existence of any Event of Default,
Holder may exercise any other right, power or remedy permitted to
it by law, either by suit in equity or by action at law, or
both.
-2-
5. Conversion
.
(a) Automatic Conversion upon
Equity Financing . Upon the closing (or first in a series of
closings) of the next equity financing in which Company sells
shares of its equity securities (the “ Equity
Securities ”) for an aggregate consideration of at least
$7,500,000 (including the aggregate principal and accrued interest
due on this Note) (the “ Equity Financing ”),
the principal and accrued interest due on this Note shall
automatically be converted into shares of the Equity Securities as
set forth in Section 5(e) below. The conversion shall be deemed to
have occurred as of the date of such closing or the date of the
first closing in a series of closings. As a condition precedent
(which may be waived by the Company) to conversion of this Note as
provided for in this Section 5(a), the Holder will be required to
execute the definitive Stock Purchase Agreement and such other
agreements prepared in connection with the Equity Financing. The
number of shares of Equity Securities into which this Note shall be
automatically converted shall be determined by dividing the
principal and accrued interest due on this Note as of the date of
conversion by an amount equal to the lesser of (i) the per share
price of the Equity Securities issued and sold in the Equity
Financing and (ii) $1.00.
(b) Automatic Conversion upon
Corporate Transaction . Upon the closing of a sale of
substantially all of the Company’s assets or a merger or
consolidation of the Company in which the Company’s
stockholders will hold, in the aggregate, less than 50% of the
voting power of the combined entity, the principal and accrued
interest due on this Note shall automatically be converted into
shares of the Company’s Common Stock as set forth in Section
5(e) below. The conversion shall be deemed to have occurred as of
the date of such closing. The number of shares of Common Stock into
which this Note shall be automatically converted shall be
determined by dividing the principal and accrued interest due on
this Note as of the date of conversion by an amount equal to the
lesser of (i) the per share price attributed to the Company’s
Common Stock in connection with such transaction and (ii)
$1.00.
(c) Automatic Conversion upon
Debt Financing . Upon consummation by the Company of the sale
and issuance of Notes in an aggregate principal amount of $10.5
million, the principal and accrued interest due on this Note shall
automatically be converted into equity securities of the Company on
terms and conditions mutually agreed upon by the Company and the
holder(s) of a majority-in-interest of then-outstanding Notes and
as set forth in Section 5(e) below. The conversion shall be deemed
to have occurred as of the date of such closing.
(d) Voluntary Conversion at
Maturity Date . At and as of the Maturity Date, to the extent
this Note is still outstanding and has not otherwise been converted
or repaid in full, the Holder will have the option, in its sole
discretion, to convert this Note into shares of the Company’s
Common Stock. The number of shares of Common Stock into which this
Note may be voluntarily converted shall be determined by dividing
the principal and accrued interest due on this Note as of the date
of conversion by $1.00.
(e) Issuance of Securities on
Conversion . As soon as practicable after conversion of this
Note, Company, at its expense, will cause to be issued in the name
of and delivered to the Holder a certificate or certificates
representing the number of fully paid and nonassessable shares of
the Equity Securities or Common Stock (as applicable) to which
Holder shall be entitled upon such conversion. No fractional shares
will be issued upon conversion of this Note.
(f) Termination of Rights .
All rights with respect to this Note shall terminate upon
conversion hereof in accordance with this Section 5, whether or not
this Note has been surrendered. Notwithstanding the foregoing, the
Holder agrees to surrender this Note to Company for cancellation as
soon as is practicable following conversion of this
Note.
-3-
6. Successors and
Assigns . Subject to
the restrictions on transfer described in Section 8 below, the
rights and obligations of Company and Holder shall be binding upon
and benefit the successors, assigns, heirs, administrators and
transferees of the parties.
7. Waiver and
Amendment . Any
provision of this Note may be amended, waived or modified upon the
written consent of Company and Holder.
8. Transfer of this Note or
Securities Issuable Upon Conversion Hereof
. With respect to any contemplated
offer, sale or other disposition of this Note or securities into
which such Note may be converted, the Holder will first give
written notice to Company prior thereto, describing briefly the
manner thereof, together with a written opinion of the
Holder’s counsel to the effect that such offer, sale or other
disposition may be effected without registration or qualification
under any federal or state law then in effect. Promptly upon
receiving such written notice and reasonably satisfactory opinion,
if so requested, Company, as promptly as practicable, shall notify
the Holder that the Holder may sell or otherwise dispose of this
Note or such securities, all in accordance with the terms of the
notice delivered to Company. If a d